Novogen Limited (NASDAQ:KZIA) Short Interest Update
by Doug Wharley · The Cerbat GemNovogen Limited (NASDAQ:KZIA – Get Free Report) saw a large growth in short interest in April. As of April 15th, there was short interest totaling 185,921 shares, a growth of 95.8% from the March 31st total of 94,933 shares. Based on an average daily volume of 225,290 shares, the short-interest ratio is currently 0.8 days. Approximately 11.4% of the company’s shares are short sold.
Wall Street Analyst Weigh In
KZIA has been the topic of several analyst reports. Wall Street Zen downgraded shares of Novogen from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Laidlaw started coverage on Novogen in a report on Wednesday, April 15th. They set a “buy” rating and a $25.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a report on Tuesday, April 21st. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Novogen in a report on Wednesday, January 28th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Novogen currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.
Get Our Latest Stock Analysis on Novogen
Novogen Stock Down 2.5%
Novogen stock traded down $0.31 during mid-day trading on Monday, reaching $11.95. 242,202 shares of the company traded hands, compared to its average volume of 276,100. The firm’s 50 day moving average price is $8.39 and its 200 day moving average price is $8.06. Novogen has a 52-week low of $3.05 and a 52-week high of $17.40.
Novogen (NASDAQ:KZIA – Get Free Report) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($1.34) earnings per share (EPS) for the quarter. The business had revenue of $4.89 million for the quarter. Research analysts anticipate that Novogen will post -0.01 EPS for the current year.
Novogen Company Profile
Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.
Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.